[Skip to Content]
[Skip to Content Landing]
From The Medical Letter on Drugs and Therapeutics
February 14, 2017

Sofosbuvir/Velpatasvir (Epclusa) for Hepatitis C

JAMA. 2017;317(6):639-640. doi:10.1001/jama.2016.12279

The FDA has approved Epclusa (Gilead), a fixed-dose combination of sofosbuvir (Sovaldi) and velpatasvir, a new direct-acting antiviral agent, for oral treatment of chronic hepatitis C virus (HCV) infection. Epclusa is the first oral combination to be approved for treatment of all six major HCV genotypes.

The prevalence of HCV genotypes in the US is about 75% for genotype 1, 20-25% for genotypes 2 and 3, and <2% for genotypes 4, 5, and 6 combined. Genotype testing is recommended to determine the optimal treatment regimen.1